Skip to main content
. Author manuscript; available in PMC: 2014 Apr 1.
Published in final edited form as: Gastroenterology. 2013 Jan 4;144(4):808–817.e15. doi: 10.1053/j.gastro.2012.12.028

Figure 1. MAGL inactivation exerts bidirection al control over endocannabinoid and eicosanoid levels during hepatic I/R.

Figure 1

(A, B) Pharmacological (A) and genetic (B) inactivation of MAGL enhances 2-AG levels but does not affect the levels of the other endocannabinoid anandamide in the liver. MAGL blockade also lowers AA and eicosanoids in the I/R livers (A, B), measured after 6 h of reperfusion (peak injury). The potent and selective MAGL inhibitor JZL184 (40 mg/kg, i.p.) was given 1 h prior to inducing ischemia in the liver and endocannabinoid and eicosanoid levels were measured after 6 h of reperfusion after ischemia by SRM-based LC-MS/MS analysis. Data represent mean±sem of n=4–5 mice/group. Significance is represented as *p<0.05 between all groups versus sham vehicle-treated groups or sham Mgll+/+ groups; #p<0.05 between JZL184-treated or Mgll−/− I/R groups and the I/R vehicle-treated or Mgll+/+ groups.